Skip to content
Screener

R&D at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.63B+14.8%
Opus Genetics logo
Opus GeneticsIRD
$10.58M+33.0%
Regenxbio logo
RegenxbioRGNX
$56.09M-5.7%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$76.48M+19.7%
Prime Medicine logo
Prime MedicinePRME
$33.4M-19.3%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$64.98M+59.7%

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.18B+85.4%
Enterprise value$1.18B+71.1%
P/S14.9×-2.0×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060739
Line itemFor the Three-Month Periods Ended March 31, 2026For the Three-Month Periods Ended March 31, 2025
Operating expenses:
Cost of service revenue - related party1981,378
General and administrative8,9289,364
Research and development31,98432,780
Total operating expenses41,11043,522
Loss from operations(40,817)(41,596)
Other non-operating income (expense):
Foreign currency (loss) gain(2,837)3,687

Item 1. Financial Statements (Unaudited)

FAQ

What is MeiraGTx Holdings plc's R&D?
MeiraGTx Holdings plc (MGTX) reported R&D of $31.98M in Q1 2026.
How has MeiraGTx Holdings plc's R&D changed year-over-year?
MeiraGTx Holdings plc's R&D decreased by 2.4% year-over-year, from $32.78M to $31.98M.
What is the long-term trend for MeiraGTx Holdings plc's R&D?
Over 4 years (2021 to 2025), MeiraGTx Holdings plc's R&D has grown at a 18.1% compound annual growth rate (CAGR), from $66.69M to $129.62M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about MeiraGTx Holdings plc's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude